Investment Rating - The report maintains a "Buy" rating for Suzhou Bank [7]. Core Views - The state-owned major shareholder has been continuously increasing its stake, indicating a strong long-term value outlook. The bank's fundamentals remain robust, with government-related business driving accelerated credit growth. The improvement in deposit costs alleviates net interest margin pressure, and the asset quality indicators are consistently excellent. The dividend payout ratio for 2024 is expected to increase by 1.4 percentage points to 32.5% of net profit attributable to the parent company, supporting a year-on-year increase in DPS. The completion of the convertible bond conversion in Q1 this year has bolstered capital, supporting credit issuance and ensuring stable future dividends. Currently, the 2025 PB valuation is 0.83x, PE valuation is 8.2x, and the expected dividend yield is 4.1% [5][9][10]. Summary by Sections Shareholder Actions - On June 30, it was announced that the major shareholder, Suzhou Guofa Group, increased its stake in Suzhou Bank, along with its concerted action partner, Dongwu Securities, to a total of 15.00%. The actual controller of Suzhou Bank has changed to the Suzhou Municipal Finance Bureau. The group plans to increase its holdings by no less than 400 million yuan over the next six months, with a commitment not to reduce its holdings within six months after the completion of this plan [5][10]. Business Performance - Suzhou Bank has shown steady growth in its core business, with total loans increasing by 8.9% year-on-year as of the end of Q1. The bank's asset scale is currently 727.2 billion yuan, with a clear path towards reaching a trillion yuan in assets. The bank's net interest margin has been under pressure due to declining loan rates, but the reduction in deposit costs is expected to stabilize this margin moving forward. The bank maintains a conservative risk appetite, with a low non-performing loan ratio and strong provisioning capabilities [9][10][11]. Financial Projections - The bank's total assets are projected to grow from 693.71 billion yuan in 2024 to 1,009.84 billion yuan by 2027. The net profit attributable to the parent company is expected to increase from 5.07 billion yuan in 2024 to 6.04 billion yuan in 2027. The bank's return on equity (ROE) is projected to be around 10.19% by 2027, with a non-performing loan ratio stabilizing at approximately 0.82% [24].

Investment Rating - The investment rating for the healthcare industry is "Positive" and is maintained [8]. Core Viewpoints - The issuance of "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission on June 30, 2025, aims to enhance the support for the entire chain of innovative drug development, promoting high-quality development of innovative drugs to better meet the diverse medical and pharmaceutical needs of the public [2][6]. Summary by Relevant Sections - **Research and Development**: There is an increased emphasis on supporting innovative drug research and development. This includes utilizing medical insurance data for R&D, encouraging commercial health insurance to expand investment in innovative drugs, and enhancing the guidance on drug directory access policies. The focus will be on major infectious diseases, prevalent chronic diseases, pediatric medications, and rare diseases to avoid homogenization in R&D [11]. - **Payment Mechanism**: The report supports the inclusion of innovative drugs in the basic medical insurance drug directory and commercial health insurance innovative drug directories. It emphasizes the need for a dynamic adjustment mechanism for the basic medical insurance drug directory and improving the professional capacity for negotiation and pricing of innovative drugs [11]. - **Application Process**: The report suggests optimizing the drug listing process, allowing companies to choose the provinces for the first listing of innovative drugs. It also encourages timely adjustments in drug supply and procurement processes in medical institutions to meet clinical needs and ensure patient access to innovative drugs [11].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a significant increase in bus sales for June 2025, with total sales reaching 5,919 units, representing a year-on-year increase of 24.8% and a month-on-month increase of 93.9%. The sales of medium and large buses were 4,998 units, up 20.1% year-on-year and 99.9% month-on-month [2][4][10] - For the first half of 2025, total bus sales amounted to 21,000 units, reflecting a year-on-year growth of 3.7%, while medium and large bus sales were 17,000 units, down 4.8% year-on-year [2][4][10] - The company is positioned as a global leader in the bus industry, showcasing strong long-term growth potential and a consistent high dividend capability, highlighting its investment value [2][10] - The domestic market is experiencing growth in seated buses, supported by the "old-for-new" policy, which is boosting the demand for new energy buses. The overseas market is benefiting from a globalization and high-end strategy, with exports enhancing profitability and supporting continuous performance improvement [2][10] Summary by Sections Sales Performance - In June 2025, the company sold 5,919 buses, with a year-on-year increase of 24.8% and a month-on-month increase of 93.9%. Medium and large bus sales were 4,998 units, up 20.1% year-on-year and 99.9% month-on-month. For the first half of 2025, total sales were 21,000 units, a 3.7% increase year-on-year, while medium and large bus sales were 17,000 units, down 4.8% year-on-year [2][4][10] Market Strategy - The company is enhancing its direct sales and service model to improve service quality and efficiency. The "old-for-new" policy is expected to continue driving the recovery of the domestic bus market. Internationally, the company is expanding its presence with a new energy commercial vehicle factory in Qatar, expected to be operational by the end of 2025, with an initial capacity of 300 units per year, expandable to 1,000 units [10] Financial Outlook - The company is projected to have a robust financial performance, with expected net profits of 48.2 billion and 56.0 billion for 2025 and 2026, respectively. The corresponding price-to-earnings ratios are estimated to be 11.9X and 10.2X [10]

Investment Rating - The report maintains a "Buy" rating for Innovent Biologics [12]. Core Insights - The first-generation immune checkpoint inhibitors (IO therapies) are facing patent expirations between 2028 and 2032, creating a significant demand for second-generation IO therapies, which are projected to have a market size of approximately $200 billion [4][7]. - The first-generation PD-1 inhibitors, represented by Keytruda (pembrolizumab) and Opdivo (nivolumab), achieved global sales of $46 billion in 2023, with an expected increase to $52.5 billion in 2024, reflecting a year-on-year growth of 18% [7][20]. - IBI363, developed by Innovent Biologics, demonstrates Best-in-Class potential through its unique PD-1 monoclonal antibody/IL-2 fusion design, showing promising results in treating both hot and cold tumors [9][68]. Summary by Sections Second-Generation IO Therapies - The second-generation IO market is categorized into three segments: replacement of first-generation IO, addressing resistance in first-generation IO, and targeting cold tumors, with a total potential market size estimated at $200 billion [7][49]. - The report highlights the urgency for multinational corporations (MNCs) to secure their positions in the next-generation cornerstone cancer therapies as first-generation patents expire [4][7]. IBI363 Molecular Design - IBI363 employs a unique PD-1 monoclonal antibody and IL-2 fusion design, achieving dual activation of effector T cells by "releasing the brake" and "pressing the accelerator" [8][56]. - The drug features a globally innovative α-biased IL-2 design, which reduces peripheral toxicity while enhancing therapeutic efficacy [57][62]. Clinical Performance of IBI363 - IBI363 has shown significant clinical benefits in various tumor types, including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC), with promising long-term overall survival (OS) trends [9][68]. - In clinical trials, IBI363 demonstrated a confirmed objective response rate (ORR) of 36.7% and a disease control rate (DCR) of 90% in squamous NSCLC patients, with a median progression-free survival (mPFS) of 9.3 months [69].

Investment Rating - The investment rating for the company is "Buy" and is maintained [11]. Core Viewpoints - The recent expectations of anti-involution in the steel industry have increased, leading to a rebound in steel prices. The government is focusing on promoting a unified national market and addressing low-price competition, which is expected to alleviate downward pressure on steel prices and help industry profits return to reasonable levels [12][13]. - The company's profitability is closely tied to steel prices, with a pricing model based on steel prices plus processing fees. If steel prices stabilize and recover, the company's profitability per ton is expected to gradually improve [12][13]. - The company has made positive changes in sales and automation this year, achieving a year-on-year increase in orders through strategic adjustments and increased investment in intelligent manufacturing equipment [12][13]. - The company currently has a safety margin, and under conservative assumptions, its market value may represent a safe bottom. With the potential for mid-term improvements from automation and a recovery in steel prices, the company is seen as a high-performance and high-odds investment opportunity [12][13]. Summary by Sections Company Basic Data - Current stock price is 17.65 CNY, with a total share capital of 69,001 million shares and a net asset per share of 13.71 CNY. The highest and lowest prices in the last 12 months were 21.50 CNY and 10.68 CNY respectively [11]. Financial Projections - Projected total revenue for 2025 is 25,247 million CNY, with a gross profit of 2,688 million CNY, maintaining a gross margin of approximately 11% [17]. - The net profit for 2025 is estimated at 930 million CNY, with earnings per share (EPS) projected to be 1.35 CNY [17]. - The company is expected to see a significant increase in cash flow from operating activities, projected at 1,064 million CNY for 2025 [17].

Core Insights - In 2025, overseas cloud service providers will significantly increase capital expenditures, accelerating the construction of computing power infrastructure, while AI terminal applications will flourish [4][11] - Telecom operators are positioned for both dividends and growth, with a continuous tilt towards intelligent computing investments [8][19] - The AI computing chain will maintain high prosperity across multiple segments, including optical modules, copper connections, liquid cooling, domestic servers, and IDC [4][9] Telecom Operators - The three major telecom operators have consistently delivered strong performance, with dividend payout ratios steadily increasing, making dividend returns attractive [8][19] - The construction of intelligent computing centers is accelerating, with a large procurement of domestic intelligent computing cards, significantly improving GPU utilization and sales rates [8][19] - Despite entering a downward cycle in total CAPEX, the proportion of computing power investments continues to rise, indicating increased investment intensity in the AI industry chain [8][19] AI Computing - In 2025, overseas cloud service providers' capital expenditures will reach a historical high, driven by demand for AI training and inference, leading to sustained high prosperity across various segments [9][30] - The demand for optical modules is rising, with significant revenue and profit growth for manufacturers in Q1 2025 [9][30] - The copper connection segment is benefiting from high-density interconnects, with manufacturers actively laying out high-speed line modules [9][30] AI Applications - AI large models are reducing costs and improving efficiency, leading to rapid evolution of AI terminal forms across various categories [10][11] - Module manufacturers are upgrading to intelligent and computing modules, significantly enhancing the value of individual products [10][11] - Companies like Guanghe Tong and Meige Intelligent are leveraging model platforms and self-developed AI stacks to empower traditional terminal upgrades [10][11] Investment Recommendations - The report recommends focusing on telecom operators such as China Mobile, China Telecom, and China Unicom, as well as key players in optical modules and domestic computing [11][19] - The current valuation of the sector remains low, offering high cost-performance for allocation [11][19] - Specific recommendations include companies like YF Communication, Huafeng Technology, and Yingweike in the domestic computing space [11][19]

Investment Rating - The report maintains a "Positive" investment rating for the industry [2]. Core Insights - The power system is a crucial component of the Tokamak fusion device, accounting for approximately 15% of the total value, with the power system comprising various elements such as magnetic power, auxiliary heating power, and energy storage systems [14][16][22]. - The report highlights the high barriers to entry in the nuclear fusion power sector, with several companies making significant progress in this field [6]. - The power supply for Tokamak devices is characterized by high power, pulsed operation, and large energy storage capacity, which poses challenges for grid stability and requires advanced energy storage solutions [17][22][90]. Summary by Sections 1. Power System as the Energy Source - The power system provides energy for critical devices like microwave heating and neutral particle injection, essential for maintaining the high-temperature plasma state required for fusion [16]. - The power system's cost breakdown shows it accounts for about 8% of the ITER device's total cost, with heating and current drive systems contributing an additional 7% [16]. 2. Magnetic Power Supply - The magnetic power supply is vital for maintaining plasma shape and stability, utilizing superconducting materials to minimize energy loss and enable high current flow [41][43]. - The report details the specifications of the magnetic power supply, including its capacity and operational parameters, emphasizing its complexity and importance in achieving successful magnetic confinement fusion [43]. 3. Auxiliary Heating Power Supply - Auxiliary heating methods are necessary to reach the temperatures required for fusion, with techniques such as Neutral Beam Injection Heating (NBIH) and Ion Cyclotron Resonance Heating (ICRH) being highlighted [51][61]. - The report outlines the components and operational principles of the auxiliary heating systems, emphasizing the need for high-voltage power supplies to support these systems [72][87]. 4. Energy Storage Systems - Energy storage technologies are identified as critical for addressing power surges in the fusion power system, with various storage methods evaluated for their effectiveness [90][92]. - The report discusses the characteristics of different energy storage technologies, including their capacity, discharge duration, and response performance, highlighting the need for a hybrid approach to meet the unique demands of fusion energy [96][98].

Investment Rating - The industry investment rating is "Positive" and maintained [12] Core Insights - Tesla's Robotaxi service officially launched in Austin, Texas, marking a significant step in the commercialization of autonomous driving, with a fleet of approximately 10 Model Y SUVs operating in designated areas [2][20] - In China, the Robotaxi commercialization process is advancing rapidly due to policy synergy and technological advantages, with the total number of taxis and licensed ride-hailing vehicles expected to reach 4-5 million by 2024, while the current market penetration of Robotaxis remains below 1% [2][8] Summary by Sections Robotaxi Commercialization Progress - Tesla's Robotaxi service began trial operations, charging a fixed fee of $4.20 per ride, with a safety driver present in each vehicle [6][20] - The U.S. companies, while slightly ahead in the commercialization timeline, face competition from Chinese firms that have achieved limited area operations with safety drivers [8][29] Technology Development Paths - The industry is characterized by two main technological approaches: Waymo's leapfrog strategy focusing on L4 autonomous driving with multi-sensor fusion, and Tesla's incremental approach using L2/L3 systems based on mass-produced vehicles [7][28] - Chinese Robotaxi companies are primarily adopting the leapfrog technology route, with significant cost advantages due to declining core component prices and local supply chain benefits [8][29] Market Potential and Cost Structure - The Robotaxi market in China is projected to grow significantly, with the total number of taxis and licensed ride-hailing vehicles expected to reach 4-5 million by 2024, while the current number of operational Robotaxis is under 3,000 [8][40] - The cost of a Robotaxi in China is approximately one-third of that of U.S. counterparts, with significant reductions in hardware costs expected in the coming years [8][39] Regulatory Environment - The regulatory landscape in China is gradually becoming more favorable for Robotaxi operations, with recent policies encouraging pilot programs and commercial operations in designated areas [32][35] - The U.S. has adopted a more open regulatory approach, allowing for rapid testing and deployment of Robotaxi services in various cities [35] Competitive Landscape - Leading Chinese Robotaxi companies include Baidu's Apollo, Pony.ai, and WeRide, which have established operations in multiple cities and are expanding their fleets [32][34] - The competition is intensifying as these companies leverage their technological advancements and cost efficiencies to capture market share both domestically and internationally [37][38]

Report Industry Investment Rating No relevant content provided. Core View of the Report In July 2025, liquidity is expected to remain relatively loose. From the perspective of bank assets and liabilities, July is not a traditional large credit month, and the maturity scale of inter - bank certificates of deposit (ICDs) in July is significantly lower than that in June. From the perspective of central bank liquidity injection, considering the external uncertainties caused by trade frictions, the central bank is expected to maintain a supportive attitude in terms of liquidity injection. However, the long - term bond yield is still at a relatively low level, and the leverage ratio in the inter - bank bond market has risen above 108% as the funding rate declines, so the room for further loosening of the funding situation is limited [8]. Summary by Relevant Catalogs 1. Funding Situation - **Central Bank's Net Injection**: From June 23 to June 27, 2025, the central bank's full - scale net injection was 126.72 billion yuan. The open - market reverse repurchase of 2027.5 billion yuan will expire from June 30 to July 4. In June, the MLF net injection was 11.8 billion yuan, and the net injection of outright reverse repurchase was 20 billion yuan [6]. - **Funding Rate**: From June 23 to June 27, 2025, the average values of DR001 and R001 were 1.37% and 1.44% respectively, with a decrease of 0.5 basis points and an increase of 0.6 basis points compared to June 16 - 20. The average values of DR007 and R007 were 1.65% and 1.82% respectively, with an increase of 12.8 basis points and 24.0 basis points compared to June 16 - 20 [7]. - **Government Bond Net Payment**: From June 23 to June 29, 2025, the government bond net payment scale was about 78.98 billion yuan, an increase of about 31.56 billion yuan compared to June 16 - 22. From June 30 to July 6, the government bond net payment scale is expected to be about - 0.594 billion yuan [7]. 2. Inter - bank Certificates of Deposit (ICDs) - **Yield Changes**: As of June 27, 2025, the maturity yields of 1M and 3M ICDs were 1.6650% and 1.6150% respectively, rising 4 basis points and 1 basis point compared to June 20, while the 1Y ICD yield was basically the same as that on June 20 [9]. - **Maturity Scale**: The ICDs have passed the peak maturity period. The maturity scale of ICDs in July is about 2.8 trillion yuan. From June 23 to June 29, 2025, the net financing of ICDs was about - 41.14 billion yuan [9]. 3. Institutional Behavior The leverage ratio in the inter - bank bond market increased. From June 23 to June 27, 2025, the average calculated leverage ratio in the inter - bank bond market was 108.45%, compared with 108.25% from June 16 to June 20 [10].

Quantitative Models and Construction Methods 1. Model Name: Optimization Replication - **Model Construction Idea**: Simplify the replication of index returns into an optimization model that minimizes tracking error[31][32] - **Model Construction Process**: 1. Define the return sequence of the portfolio as: $ \tilde{R}_{t} = \Sigma_{i=1}^{M} \widetilde{W}_{i,t} \cdot Y_{i,t} = Y_{t} \cdot \overline{W}_{t} $ where $ \widetilde{W}_{i,t} $ represents the weight of asset $i$ at time $t$, and $Y_{i,t}$ is the return of asset $i$ at time $t$[31] 2. Minimize the tracking error (TE): $ w = arg\,min\;TE $ $ TE = \frac{1}{T} \Sigma_{t=1}^{T} (\tilde{R}_{t} - R_{t})^2 $ where $R_{t}$ is the benchmark return at time $t$[32] 3. Add constraints: - Full investment: $ \Sigma_{i=1}^{N} w_{i} = 1 $ - Non-negativity: $ 0 \leq w_{i} \leq 1 $[33][35] 4. Incorporate style and industry neutrality constraints to reduce overfitting: $ z_{low} \leq \frac{X_{s}^{T}w - X_{s}^{T}\tilde{w}}{s_{b}} \leq z_{up} $ $ w_{low}^{I} \leq X_{I}^{T}w - X_{I}^{T}\bar{w} \leq w_{up}^{I} $[36] 5. Solve the optimization problem to determine the weights of individual stocks[37] 2. Model Name: Pair Trading - **Model Construction Idea**: Identify pairs of stocks or sectors with similar trends and exploit mean-reversion characteristics to generate excess returns[57] - **Model Construction Process**: 1. Identify pairs of stocks or sectors with stable relationships based on quantitative or fundamental analysis 2. Overweight weaker-performing assets and underweight stronger-performing ones 3. Capture excess returns when the price spread reverts to its mean, particularly during events like macroeconomic data releases or seasonal effects[57] --- Model Backtesting Results 1. Optimization Replication - **Annualized Return**: 5.76% - **Excess Return**: 3.74% - **Sharpe Ratio**: 0.41 - **Excess Drawdown**: 3.86% - **Excess Win Rate**: 72% - **Information Ratio (IR)**: 1.51 - **Tracking Error**: 2.22%[23][27] --- Quantitative Factors and Construction Methods 1. Factor Name: Quantitative Multi-Factor - **Factor Construction Idea**: Select long-term effective alpha factors and construct a multi-factor portfolio to achieve stable excess returns[46] - **Factor Construction Process**: 1. Define the multi-factor model: $ \begin{bmatrix} r_{1} \\ r_{2} \\ \vdots \\ r_{n} \end{bmatrix} = \begin{bmatrix} x_{11} \\ x_{21} \\ \vdots \\ x_{n1} \end{bmatrix} f_{1} + \begin{bmatrix} x_{12} \\ x_{22} \\ \vdots \\ x_{n2} \end{bmatrix} f_{2} + \cdots + \begin{bmatrix} x_{1m} \\ x_{2m} \\ \vdots \\ x_{nm} \end{bmatrix} f_{m} + \begin{bmatrix} u_{1} \\ u_{2} \\ \vdots \\ u_{n} \end{bmatrix} $ where $r_{i}$ is the excess return of stock $i$, $x_{ij}$ is the exposure of stock $i$ to factor $j$, and $f_{j}$ is the return of factor $j$[46] 2. Select effective single factors, such as volatility, short-selling intention, and liquidity, based on theoretical direction and empirical validation[48] 3. Construct a multi-factor portfolio by combining these factors and optimizing weights[47] 2. Factor Name: Negative Enhancement - **Factor Construction Idea**: Underweight stocks expected to underperform or incur losses, leveraging negative factors or events to generate stable excess returns[56] - **Factor Construction Process**: 1. Identify stocks with negative attributes, such as analyst downgrades, equity pledges, or poor earnings reports 2. Underweight these stocks in the portfolio to reduce potential losses and achieve alpha[56] 3. Factor Name: Machine Learning-Based Alpha - **Factor Construction Idea**: Use deep learning models like TCN (Temporal Convolutional Networks) to extract complex and effective alpha factors from price and volume data[52] - **Factor Construction Process**: 1. Train neural networks on historical price and volume data to identify patterns and relationships 2. Generate alpha factors that outperform traditional genetic programming methods in terms of depth and complexity[51][52] --- Factor Backtesting Results 1. Quantitative Multi-Factor - **Excess Return**: Stable across long-term horizons - **Key Factors**: Volatility, short-selling intention, liquidity, and local pricing[48] 2. Negative Enhancement - **Excess Return**: Achieved through underweighting stocks with negative attributes or events[56] 3. Machine Learning-Based Alpha - **Performance**: Demonstrated superior results compared to traditional factor generation methods[52] --- Index Enhancement Methods 1. IPO Enhancement - **Annualized Return**: 2.13% in 2025 - **Segment Performance**: Sci-Tech Innovation Board (4.34%), ChiNext (2.52%)[67][68] 2. Stock Index Futures - **Annualized Basis Spread**: - CSI 300: -6.75% - SSE 50: -2.48% - CSI 500: -13.60% - CSI 1000: -18.09%[72][73] 3. Block Trades - **Median Discount Rate**: 5.38% (2017-2025), 8.23% in 2025[74][75] 4. Private Placements - **Median Discount Rate**: 14.55% (2017-2025), 11.87% in 2025[77]